Switching from Tenofovir Disoproxil to Tenofovir Alafenamide Fumarate: Impact on Cardiovascular Risk and Lipid Profile in People Living with HIV, an Observational Study.

MLA

Moschopoulos, Charalampos D., et al. “Switching from Tenofovir Disoproxil to Tenofovir Alafenamide Fumarate: Impact on Cardiovascular Risk and Lipid Profile in People Living with HIV, an Observational Study.” AIDS Research & Human Retroviruses, vol. 39, no. 2, Feb. 2023, pp. 68–75. EBSCOhost, https://doi.org/10.1089/aid.2022.0086.

APA

Moschopoulos, C. D., Protopapas, K., Thomas, K., Kavatha, D., Papadopoulos, A., & Antoniadou, A. (2023). Switching from Tenofovir Disoproxil to Tenofovir Alafenamide Fumarate: Impact on Cardiovascular Risk and Lipid Profile in People Living with HIV, an Observational Study. AIDS Research & Human Retroviruses, 39(2), 68–75. https://doi.org/10.1089/aid.2022.0086

Chicago

Moschopoulos, Charalampos D., Konstantinos Protopapas, Konstantinos Thomas, Dimitra Kavatha, Antonios Papadopoulos, and Anastasia Antoniadou. 2023. “Switching from Tenofovir Disoproxil to Tenofovir Alafenamide Fumarate: Impact on Cardiovascular Risk and Lipid Profile in People Living with HIV, an Observational Study.” AIDS Research & Human Retroviruses 39 (2): 68–75. doi:10.1089/aid.2022.0086.